A Phase Ib trial of a personalized neoantigen dendritic cell vaccine in newly diagnosed glioblastoma reported early clinical activity, according to results published in Nature Communications. The approach uses autologous dendritic cells pulsed with patient-specific neoantigens to drive tumor-targeted immune responses. The study focuses on patients early in their disease course and evaluates safety alongside immunologic and clinical readouts. For glioblastoma—a setting where durable responses remain rare—personalized neoantigen vaccination is aimed at improving specificity of immune activation against each patient’s tumor. While Phase Ib data are not definitive for efficacy, the report adds another data point to the expanding field of individualized cellular immunotherapies in aggressive brain tumors.